Sep 27, 2023

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

➞

Sep 26, 2023

Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador

➞

Sep 22, 2023

FDA Grants Fast Track Designation to 9MW3011

➞

Sep 06, 2023

Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics

➞

Sep 05, 2023

Mabwell Announces the First Patient Dosed in the Clinical Studies of 2 Novel ADCs

➞

Aug 28, 2023

Mabwell Partners with UNILAB to Market its Adalimumab Biosimilar in the Philippines

➞

Jul 31, 2023

Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Morocco Market

➞

Jul 21, 2023

Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023

➞

Jul 17, 2023

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

➞

Jul 14, 2023

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND

➞